Stellar Biotechnologies Overview

  • Founded
  • 1999
Founded
  • Status
  • Public
  • Employees
  • 10
Employees
  • Stock Symbol
  • EDSA
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $9.45
  • (As of Thursday Closing)

Stellar Biotechnologies General Information

Description

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

Contact Information

Formerly Known As
CAG CAPITAL
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 332 East Scott Street
  • Port Hueneme, CA 93041
  • United States
+1 (805) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Stellar Biotechnologies Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.45 $5.20 $1.58 - $19.10 $83.7M 8.86M 1.77M

Stellar Biotechnologies Financials Summary

In Thousands,
USD
TTM 31-Mar-2019 FY 2018 30-Sep-2018 FY 2017 30-Sep-2017 FY 2016 30-Sep-2016
EV (3,153) (3,874) 4,292 17,541
Revenue 298 212 228 1,272
EBITDA (5,174) (4,850) (4,851) (4,869)
Net Income (5,348) (5,039) (5,031) (5,026)
Total Assets 9,151 11,780 7,720 12,938
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Stellar Biotechnologies Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Stellar Biotechnologies‘s full profile, request access.

Request a free trial

Stellar Biotechnologies Executive Team (6)

Name Title Board Seat Contact Info
Kathi Niffenegger Chief Financial Officer, Finance
Catherine Brisson Ph.D Chief Operating Officer
You’re viewing 2 of 6 executive team members. Get the full list »

Stellar Biotechnologies Board Members (6)

Name Representing Role Since
00000 00000 Stellar Biotechnologies Board Member 000 0000
00000 0000000 00.0 Self Board Member 000 0000
000000 000000000 000000 Self Board Member 000 0000
You’re viewing 3 of 6 board members. Get the full list »

Stellar Biotechnologies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Stellar Biotechnologies Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 19-Jul-2016 00000 0000000 Pharmaceuticals 00000 00000
To view Stellar Biotechnologies’s complete investments history, request access »